Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Vemurafenib-induced toxic epidermal necrolysis].

Annales de dermatologie et de venereologie - 1 Mar 2014

Wantz M, Spanoudi-Kitrimi I, Lasek A, Lebas D, Quinchon J-F, Modiano P

Abstract excerpt

BACKGROUND: Herein we report the first case of toxic epidermal necrolysis (TEN) occurring with use of vemurafenib. PATIENTS AND METHODS: A 75-year-old female patient was being treated with vemurafenib for stage IV melanoma with BRAF V600E mutation. She suddenly presented fever, diffuse pruriginou...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Indoles
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Skin Neoplasms

Share to Stevens-Johnson Syndrome

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 24635957
DOI: 10.1016/j.annder.2013.10.054

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24635957-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Vemurafenib-induced toxic epidermal necrolysis].PMID 24635957Read ↗

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read ↗

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

[Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].Semantic proximity Read ↗

Nonmalignant cutaneous findings associated with vemurafenib.Semantic proximity Read ↗

Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.Semantic proximity Read ↗

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.Semantic proximity Read ↗

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read ↗

Vemurafenib-induced bilateral facial palsy.Semantic proximity Read ↗

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.